EARS Research and Charts

EARS - Auris Medical Holding Ltd (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2024-12-19)

Last 0.30	Change ⇓ -0.11 (0.00%)	Volume 830,271
	Open 0.42	High 0.43	Low 0.30

8EMA (Daily) 0.41	40EMA (Daily) 0.48	50EMA (Daily) 0.51	STO (Daily) 7.778	MACD Hist (Daily) -0.019
8EMA (Weekly) 0.454	40EMA (Weekly) 0.91	50EMA (Weekly) 0.99	STO (Weekly) 7.262	MACD Hist (Weekly) -0.009


Company Profile
Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops therapeutics that address important unmet medical needs in neurotology, rhinology, allergy, and CNS disorders. It has two projects in clinical development: Keyzilen for the treatment of acute inner ear tinnitus and Sonsuvi for the treatment of acute inner ear hearing loss. Its other product candidates are AM-125, AM-201, and AM-301.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.